Participants 16 152 6
exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
Participants 462 563 5
treatment-naive patients with HCV genotype 1 infection enrolled in a large expanded access programme.
Participants 572 688 9
Eight hundred and ninety-one patients treated for 48 weeks with an initial ribavirin dose of 800 or 1000/1200 mg/day
